UiPath used its Fusion 25 stage to shift automation from one-off tasks to orchestrated systems. New tools for documents and testing, plus pre-built industry solutions, frame its case for agentic ...

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the drug to peak ...

UiPath Inc. has a robust net cash balance sheet, near-term GAAP profitability & potential for accelerating top-line growth. Read why PATH stock is a Buy.

UiPath has a better P/E ratio of 484.0 than the aggregate P/E ratio of 77.56 of the Software industry. Ideally, one might believe that UiPath Inc. might perform better in the future than it's industry ...

Wesco Distribution’s automation lead Max Ioffe has built a program where the business owns the bots — not the other way around. His team’s mix of orchestration, AI agents, and grassroots adoption ...

UiPath stock could have a strong upside if these partnerships can help reaccelerate revenue growth.

According to Benzinga Pro, UiPath Inc's peer group average for short interest as a percentage of float is 5.82%, which means the company has more short interest than most of its peers. Did you know ...

UiPath's new products and collaborations with Nvidia, Microsoft, Snowflake, Alphabet, and OpenAI aim to accelerate AI adoption. Read why PATH stock is a Buy.

UiPath (PATH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Fintel reports that on October 2, 2025, BMO Capital maintained coverage of UiPath (NYSE:PATH) with a Market Perform recommendation. Analyst Price Forecast Suggests 4.58% Upside As of September 29, ...

Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced Snowflake Cortex AI for Financial Services, a comprehensive suite of AI capabilities and partnerships that empower financial services ...